EA201491155A1 - Новые мутантные про-нрф и их применение для получения бета-нрф - Google Patents
Новые мутантные про-нрф и их применение для получения бета-нрфInfo
- Publication number
- EA201491155A1 EA201491155A1 EA201491155A EA201491155A EA201491155A1 EA 201491155 A1 EA201491155 A1 EA 201491155A1 EA 201491155 A EA201491155 A EA 201491155A EA 201491155 A EA201491155 A EA 201491155A EA 201491155 A1 EA201491155 A1 EA 201491155A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nrf
- mutant pro
- pro
- beta
- application
- Prior art date
Links
- 101001051709 Homo sapiens Ribosomal protein S6 kinase-related protein Proteins 0.000 abstract 1
- 102100024914 Ribosomal protein S6 kinase-related protein Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к мутантным про-НРФ и их применению, в частности применению мутантного про-НРФ для получения человеческого бета-НРФ. В изобретении раскрывается способ получения биологически активного человеческого бета-НРФ из неактивного нерастворимого мутантного про-НРФ. Мутантный про-НРФ замещен любой аминокислотой, кроме Arg или Lys нативного участка RSKR, по меньшей мере, в позициях Rи K, соответствующих позиции 101 и 103 человеческой про-НРФ последовательности.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11194208 | 2011-12-19 | ||
| PCT/EP2012/076251 WO2013092776A1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491155A1 true EA201491155A1 (ru) | 2015-01-30 |
| EA031333B1 EA031333B1 (ru) | 2018-12-28 |
Family
ID=47428641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491155A EA031333B1 (ru) | 2011-12-19 | 2012-12-19 | Новые мутантные про-нрф и их применение для получения бета-нрф |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9617322B2 (ru) |
| EP (2) | EP2907521B1 (ru) |
| JP (4) | JP6039146B2 (ru) |
| KR (2) | KR20160120788A (ru) |
| CN (2) | CN109400693A (ru) |
| AU (1) | AU2012357052B2 (ru) |
| BR (1) | BR112014014913B1 (ru) |
| CA (1) | CA2859262C (ru) |
| CY (2) | CY1117016T1 (ru) |
| DK (2) | DK2672984T3 (ru) |
| EA (1) | EA031333B1 (ru) |
| ES (2) | ES2657344T3 (ru) |
| HR (2) | HRP20150900T1 (ru) |
| HU (2) | HUE027245T2 (ru) |
| IL (1) | IL233137A0 (ru) |
| LT (1) | LT2907521T (ru) |
| MX (2) | MX353074B (ru) |
| NO (1) | NO2907521T3 (ru) |
| PL (2) | PL2672984T3 (ru) |
| PT (2) | PT2907521T (ru) |
| RS (2) | RS54220B1 (ru) |
| SG (2) | SG11201402585PA (ru) |
| SI (2) | SI2672984T1 (ru) |
| SM (2) | SMT201800097T1 (ru) |
| TR (1) | TR201802360T4 (ru) |
| WO (1) | WO2013092776A1 (ru) |
| ZA (1) | ZA201403753B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109400693A (zh) | 2011-12-19 | 2019-03-01 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| US20160220639A1 (en) * | 2013-09-11 | 2016-08-04 | New York University | Methods and compositions for treating bone diseases |
| EP3406259A1 (en) | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| CN108456681B (zh) * | 2018-03-26 | 2019-10-11 | 江苏中新医药有限公司 | 高效表达重组人神经生长因子的基因组合 |
| EP3784691A1 (en) | 2018-04-27 | 2021-03-03 | Chiesi Farmaceutici S.p.A. | Production of nerve growth factor (ngf) and of muteins thereof |
| JP7340863B2 (ja) * | 2018-06-29 | 2023-09-08 | 学校法人同志社 | エムリカサンを含む製剤 |
| JP2022502359A (ja) | 2018-09-17 | 2022-01-11 | キエージ・フアルマチエウテイチ・エツセ・ピ・ア | 皮膚科障害の処置のための薬剤 |
| IT201900014646A1 (it) * | 2019-08-12 | 2021-02-12 | Consiglio Nazionale Ricerche | Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee |
| CN114401737A (zh) * | 2019-09-17 | 2022-04-26 | 奇斯药制品公司 | 用于治疗或预防眼科病症的药剂 |
| IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packages comprising polypropylene containers and ngf aqueous formulations packaged therein |
| EP4039269A1 (en) | 2021-02-05 | 2022-08-10 | Dompe' Farmaceutici S.P.A. | Ngf isoform for use in the treatment of ocular pathologies |
| CA3215298A1 (en) | 2021-04-13 | 2022-10-20 | Pedram HAMRAH | Treatment of neuropathic corneal pain with ngf |
| EP4311554A1 (en) | 2022-07-29 | 2024-01-31 | Dompé farmaceutici S.p.a. | Combination for use in ophthalmology |
| EP4316505A1 (en) | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| EP4342485A1 (en) | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
| EP4497431A1 (en) | 2023-07-27 | 2025-01-29 | Dompé farmaceutici S.p.A. | Pharmaceutical formulation comprising nerve growth factor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4139000A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf |
| BR9712824A (pt) * | 1996-09-13 | 1999-12-21 | Advanced Medicine Research Ins | Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico |
| EP0994188B1 (de) | 1998-10-09 | 2004-01-07 | Scil proteins GmbH | Verfahren zur Gewinnung von aktivem Beta-NGF |
| US20030040082A1 (en) | 2001-02-16 | 2003-02-27 | Mark Tuszynski | Mutant pro-neurotrophin with improved activity |
| ATE554784T1 (de) | 2001-05-25 | 2012-05-15 | Cornell Res Foundation Inc | Hochaffiner ligand für p75 neurotrophin-rezeptor |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| EP1709161B1 (en) | 2004-01-19 | 2008-10-01 | Nsgene A/S | Human therapeutic cells secreting nerve growth factor |
| US20080050776A1 (en) * | 2006-05-26 | 2008-02-28 | Kenneth Neet | Stable mutated pro nerve growth factors |
| CN101260398B (zh) | 2007-03-07 | 2013-06-05 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
| CN109400693A (zh) | 2011-12-19 | 2019-03-01 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
-
2012
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/zh active Pending
- 2012-12-19 SM SM20180097T patent/SMT201800097T1/it unknown
- 2012-12-19 PL PL12805695T patent/PL2672984T3/pl unknown
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 RS RS20150561A patent/RS54220B1/en unknown
- 2012-12-19 RS RS20180159A patent/RS56893B1/sr unknown
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en active Application Filing
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/pt active IP Right Grant
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/lt unknown
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/es active Active
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/zh active Active
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/tr unknown
- 2012-12-19 PT PT151573201T patent/PT2907521T/pt unknown
- 2012-12-19 PL PL15157320T patent/PL2907521T3/pl unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/es active Active
- 2012-12-19 MX MX2014007317A patent/MX353074B/es active IP Right Grant
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/ja active Active
- 2012-12-19 PT PT128056959T patent/PT2672984E/pt unknown
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 SI SI201230289T patent/SI2672984T1/sl unknown
- 2012-12-19 MX MX2017012894A patent/MX370861B/es unknown
- 2012-12-19 EA EA201491155A patent/EA031333B1/ru unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/ko not_active Withdrawn
- 2012-12-19 HR HRP20150900TT patent/HRP20150900T1/hr unknown
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/ko active Active
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/hu unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
-
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
-
2015
- 2015-08-20 SM SM201500201T patent/SMT201500201B/xx unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/el unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
-
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/ja active Active
-
2018
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/hr unknown
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/el unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/ja active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/ja active Pending
-
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
| EA201290988A1 (ru) | Стереоселективный синтез фосфорсодержащих активных соединений | |
| EA201490521A1 (ru) | Варианты фактора роста фибробластов 21 | |
| NZ601374A (en) | Stabilized antibody-containing liquid formulations | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| EA201390739A1 (ru) | Способ лечения fgf21-ассоциированных расстройств | |
| CU20140034A7 (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| EA201490697A1 (ru) | Белки с двойной функцией для лечения метаболических расстройств | |
| EA201171043A1 (ru) | Композиции и способы длительной терапии с применением аминопиридинов | |
| EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
| MY200925A (en) | Peptide Amide Compound and Preparation Method and Medical use Thereof | |
| EA201600088A1 (ru) | Парентеральное введение тапентадола | |
| EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| EA201290961A1 (ru) | Способы применения растворимого cd24 для лечения ревматоидного артрита | |
| PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
| PL415888A1 (pl) | Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie | |
| EA201992516A1 (ru) | Способ получения бифункциональных белков и их производных | |
| UY34314A (es) | Derivados de anilina, su preparación y su aplicación terapéutica. | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| EA201391097A1 (ru) | СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА | |
| CY1118786T1 (el) | Ακλιδινιο για χρηση στη βελτιωση της ποιοτητας του υπνου σε ασθενεις με αναπνευστικες παθησεις | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
| RU2507212C3 (ru) | Способ получения рекомбинантного пептида и полученный пептид |